You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 8, 2024

CLINICAL TRIALS PROFILE FOR GADOTERATE MEGLUMINE

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for GADOTERATE MEGLUMINE

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00650845 ↗	Renal Safety Evaluation After Dotarem®-Enhanced MRI	Completed	Guerbet	Phase 4	2008-01-01	Although there is a well documented risk of acute renal failure with the iodinated contrast agents, the implication of intravenous gadolinium-based contrast agents in nephrotoxicity remains controversial. The aim of this study was to evaluate the safety profile of gadoterate meglumine (Dotarem®) in patients with chronic renal insufficiency by evaluating the rate of patients experiencing contrast-induced nephrotoxicity following the injection of gadoterate meglumine.
NCT01010932 ↗	Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)	Completed	Guerbet	Phase 3	2009-10-01	The study will evaluate the efficacy and safety of Dotarem enhanced MRA in patients suffering from carotid or vertebral arterial disease.
NCT01012674 ↗	Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)	Completed	Guerbet	Phase 3	2009-10-01	The study will evaluate the efficacy and safety of Dotarem enhanced MRA in patients suffering from carotid or vertebral arterial disease.
NCT01254552 ↗	Assessment With CCTA and MRI in Asymptomatic Patients With Type 2 Diabetes for Detection of Unrecognized Myocardial Scar in Subclinical Coronary Atherosclerosis	Completed	Guerbet	Phase 4	2010-08-01	The study aimed to prospectively investigate the prevalence of myocardial scar on Dotarem-enhanced Cardiovascular Magnetic Resonance Imaging (MRI) in asymptomatic patients with type-2 Diabetes Mellitus and to assess its correlation with subclinical coronary artery disease on Cardiac Computed Tomography Angiography (CCTA).
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for GADOTERATE MEGLUMINE

Condition Name

Chart
Table

Condition Name for GADOTERATE MEGLUMINE
Intervention	Trials
Breast Diseases	2
Cerebral Arterial Diseases	2
Contrast Enhancement in Magnetic Resonance Imaging	2
Contrast Media	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for GADOTERATE MEGLUMINE
Intervention	Trials
Cerebral Arterial Diseases	2
Renal Insufficiency	2
Breast Diseases	2
Breast Neoplasms	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for GADOTERATE MEGLUMINE

Trials by Country

Map
Table

Trials by Country for GADOTERATE MEGLUMINE
Location	Trials
United States	30
Japan	20
China	9
Korea, Republic of	9
Germany	8
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for GADOTERATE MEGLUMINE
Location	Trials
Illinois	4
North Carolina	3
Massachusetts	3
Florida	2
Connecticut	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for GADOTERATE MEGLUMINE

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for GADOTERATE MEGLUMINE
Clinical Trial Phase	Trials
Phase 4	6
Phase 3	5
Phase 2	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for GADOTERATE MEGLUMINE
Clinical Trial Phase	Trials
Completed	7
Recruiting	6
Not yet recruiting	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for GADOTERATE MEGLUMINE

Sponsor Name

Chart
Table

Sponsor Name for GADOTERATE MEGLUMINE
Sponsor	Trials
Guerbet	11
Bayer	2
GEHC (Sponsor)	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for GADOTERATE MEGLUMINE
Sponsor	Trials
Industry	14
Other	10
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.